BioNTech SE (NASDAQ:BNTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of BioNTech SE (NASDAQ:BNTX) have been assigned a consensus recommendation of “Moderate Buy” from the sixteen analysts that are currently covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $138.64.

BNTX has been the topic of a number of research reports. The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and upped their price objective for the company from $90.00 to $137.00 in a report on Friday, November 8th. JPMorgan Chase & Co. lowered their price target on shares of BioNTech from $124.00 to $122.00 and set a “neutral” rating on the stock in a research report on Tuesday. Evercore ISI raised shares of BioNTech from an “in-line” rating to an “outperform” rating and boosted their price objective for the company from $110.00 to $125.00 in a report on Tuesday, November 19th. TD Cowen lowered their target price on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating on the stock in a report on Tuesday, November 5th. Finally, UBS Group boosted their price target on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a research note on Wednesday, September 18th.

Hedge Funds Weigh In On BioNTech

A number of institutional investors have recently added to or reduced their stakes in the stock. FMR LLC increased its holdings in BioNTech by 797.8% in the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company’s stock worth $748,243,000 after purchasing an additional 5,598,190 shares in the last quarter. Fred Alger Management LLC acquired a new position in shares of BioNTech in the third quarter valued at approximately $59,485,000. Candriam S.C.A. raised its holdings in BioNTech by 261.2% in the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock valued at $46,526,000 after buying an additional 418,695 shares during the last quarter. Point72 Asset Management L.P. boosted its position in BioNTech by 283.5% during the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock worth $37,103,000 after buying an additional 341,311 shares during the period. Finally, Braidwell LP acquired a new stake in BioNTech during the 3rd quarter worth approximately $29,425,000. 15.52% of the stock is currently owned by institutional investors and hedge funds.

BioNTech Price Performance

Shares of BNTX opened at $118.54 on Wednesday. The company’s 50-day moving average is $113.54 and its 200-day moving average is $98.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The firm has a market capitalization of $28.42 billion, a PE ratio of -56.45 and a beta of 0.26. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The firm had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. During the same period last year, the business posted $0.73 earnings per share. The business’s revenue for the quarter was up 38.9% compared to the same quarter last year. Equities analysts forecast that BioNTech will post -3.68 EPS for the current year.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.